I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office on the date shown below:

INFORMATION DISCLOSURE STATEMENT Patent Application Docket No. GJE-7705

May 25, 7007

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not yet assigned

Applicants : Andrew Douglas Baxter et al.

Serial No. : 10/591,137

Filed: August 30, 2006

Conf. No. : 7780 Art Unit : 1751

For : The Treatment of Inflammatory Disorders and Pain Using Beta-

Aminoalcohols

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 USC §371. A copy of the International Search Report is attached for the Examiner's convenience. Copies of these documents are attached with this IDS.

In accordance with 37 CFR §1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100 Fax No.: 352-372-5800 Address: P.O. Box 142950

Gainesville, FL 32614-2950

DRS/la

Attachments: Form PTO/SB/08 (2 pages)

Copy of International Search Report Copies of cited references (21)